Catalist:42CPharmaceuticals
IX Biopharma (Catalist:42C) H1 Loss Of S$2.1 Million Reinforces Profitability Concerns
iX Biopharma (Catalist:42C) has released its H1 2026 numbers, reporting revenue of S$3.2 million and a basic EPS loss of S$0.00226. This continues to draw attention to the company’s path toward profitability. The company’s half yearly revenue moved from S$3.7 million in H1 2025 to S$4.1 million in H2 2025 and then to S$3.2 million in H1 2026. Over the same periods, basic EPS losses were S$0.00717, S$0.00442 and S$0.00226, respectively, leaving investors focused on how much of each sales...